Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Guardant Health, Inc.

GH Nasdaq Services-Medical Laboratories Financials FY2016โ€“FY2025

Last close ยท Oct 23, 2026

$169.08

3.8%
Compare
Revenue Total sales reported in the income statement.
$982M
32.9% vs prior year
Operating margin Operating income as a share of revenue.
โˆ’44.5%
15.5ย pts
Net income Profit after all expenses, interest and tax.
โˆ’$416M
Free cash flow Cash from operations minus capital spending.
โˆ’$233M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โˆ’170.1%
45.0ย pts
Market cap Last close times the latest diluted share count, so it is approximate.
$22.5B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$3.50 EPS (TTM)

What Guardant Health, Inc. does

No business description yet.

Legal name
Guardant Health, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K ยท Feb 19, 2026
Accession ยท CIK
0001576280-26-000013
0001576280

Revenue and margins

Guardant Health, Inc. had $982M of revenue in fiscal 2025, up 32.9% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โˆ’$233M in fiscal 2025, โˆ’23.7% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Guardant Health, Inc. returned $45.0M to shareholders in fiscal 2025. The diluted share count rose 2.1%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Guardant Health, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $933M$1.0B$1.2B$840M$1.2B
Debt incl. finance leases โ€”โ€”โ€”$1.1B$1.5B
Interest coverage โˆ’159.5xโˆ’211.2xโˆ’219.1xโˆ’171.9xโˆ’112.2x
Current ratio 5.7x6.2x6.5x4.7x4.8x
Quick ratio 5.6x5.9x6.2x4.4x4.6x
Total assets $2.2B$1.6B$1.8B$1.5B$2.0B
Total liabilities $1.6B$1.5B$1.6B$1.6B$2.1B
Shareholders' equity $645M$60.2M$159Mโˆ’$140Mโˆ’$99.3M
Net debt (โˆ’ = net cash) โ€”โ€”โ€”$303M$302M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Cash from operations is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Return on assets rose โ€” โ€” โœ“ โœ“ โœ• โœ• โœ• โœ“ โœ• โœ“
Cash from operations exceeds net income โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ“
Debt fell relative to assets โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โœ“
Current ratio rose โ€” โ€” โœ• โœ• โœ“ โœ• โœ“ โœ“ โœ• โœ“
Share count didn't rise โ€” โœ“ โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Gross margin rose โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โœ“ โœ“
Revenue rose relative to assets โ€” โ€” โœ“ โœ“ โœ• โœ“ โœ“ โœ“ โœ“ โœ•
F-score โ€” / 3โ€” / 43 / 73 / 72 / 72 / 73 / 74 / 73 / 85 / 9
Accruals ratio โ€”โˆ’3.2%โˆ’2.8%โˆ’3.7%โˆ’8.8%โˆ’7.9%โˆ’18.1%โˆ’9.1%โˆ’12.0%โˆ’13.2%
Altman Z'' โ€”10.3510.229.125.120.43โˆ’1.53โˆ’1.74โˆ’4.09โˆ’2.57

10 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $25.2M $49.8M $90.6M $214M $287M $374M $450M $564M $739M $982M
Gross profit โ€” โ€” โ€” โ€” โ€” โ€” โ€” $337M $449M $633M
Research and development $10.9M $25.6M $50.7M $86.3M $150M $263M $374M $367M $348M $364M
Operating income โˆ’$43.8M โˆ’$76.6M โˆ’$92.9M โˆ’$82.4M โˆ’$255M โˆ’$411M โˆ’$544M โˆ’$565M โˆ’$444M โˆ’$437M
Interest expense $3.0M $2.7M $1.3M $1.2M $4.8M $2.6M $2.6M $2.6M $2.6M $3.9M
Pretax income โˆ’$46.1M โˆ’$83.2M โˆ’$84.2M โˆ’$69.7M โˆ’$246M โˆ’$384M โˆ’$653M โˆ’$479M โˆ’$435M โˆ’$418M
Income tax $0.0M $0.0M $0.0M โˆ’$1.9M $0.4M $0.3M $1.1M $0.7M $1.3M โˆ’$1.3M
Net income โˆ’$46.1M โˆ’$83.2M โˆ’$85.1M โˆ’$75.7M โˆ’$246M โˆ’$385M โˆ’$655M โˆ’$479M โˆ’$436M โˆ’$416M
Net income to common โˆ’$46.1M โˆ’$89.0M โˆ’$85.1M โˆ’$75.7M โˆ’$254M โˆ’$406M โˆ’$655M โˆ’$479M โˆ’$436M โˆ’$416M
Diluted EPS โˆ’$3.53 โˆ’$7.07 โˆ’$2.80 โˆ’$0.84 โˆ’$2.60 โˆ’$4.00 โˆ’$6.41 โˆ’$4.28 โˆ’$3.56 โˆ’$3.32
Diluted shares 0.01B 0.01B 0.03B 0.09B 0.10B 0.10B 0.10B 0.11B 0.12B 0.13B
Cash flow
Cash from operations โˆ’$36.7M โˆ’$72.2M โˆ’$72.2M โˆ’$47.1M โˆ’$104M โˆ’$209M โˆ’$309M โˆ’$325M โˆ’$240M โˆ’$185M
Capital expenditure $1.8M $6.7M $20.2M $18.7M $36.2M $75.0M $77.5M $20.5M $35.1M $48.3M
Free cash flow โˆ’$38.5M โˆ’$78.9M โˆ’$92.4M โˆ’$65.9M โˆ’$140M โˆ’$284M โˆ’$387M โˆ’$345M โˆ’$275M โˆ’$233M
Depreciation and amortization $3.7M $5.2M $7.1M $11.4M $16.1M $22.3M $36.0M $42.9M $42.4M $39.7M
Stock-based compensation $2.0M $3.7M $6.9M $17.0M $144M $151M $94.7M $90.8M $140M $166M
Acquisitions โ€” $0.0M $0.0M $7.3M $0.0M $0.0M โ€” $0.0M $0.0M $59.0M
Share buybacks $0.1M $7.2M $0.2M $0.0M $0.0M โ€” โ€” $0.0M $0.0M $45.0M
Dividends and buybacks $0.1M $7.2M $0.2M $0.0M $0.0M โ€” โ€” $0.0M $0.0M $45.0M
Balance sheet
Cash and short-term investments $33.6M $221M $419M $523M $1.8B $933M $1.0B $1.2B $840M $1.2B
Total debt โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” $1.1B $1.5B
Current assets โ€” $243M $469M $597M $1.9B $1.1B $1.2B $1.3B $1.1B $1.5B
Current liabilities โ€” $19.6M $46.9M $72.7M $66.8M $195M $193M $206M $226M $303M
Inventory โ€” $7.3M $9.1M $15.2M $22.7M $30.7M $51.6M $61.9M $71.1M $85.9M
Property and equipment, net โ€” $16.0M $31.0M $43.7M $62.8M $124M $168M $145M $137M $146M
Goodwill โ€” โ€” $0.0M $3.3M $3.3M $3.3M $3.3M $3.3M $3.3M $77.3M
Intangible assets โ€” โ€” $0.0M $8.5M $16.2M $14.2M $11.7M $9.0M $6.8M $25.9M
Total assets โ€” $343M $587M $963M $2.3B $2.2B $1.6B $1.8B $1.5B $2.0B
Total liabilities โ€” $34.3M $62.5M $115M $916M $1.6B $1.5B $1.6B $1.6B $2.1B
Shareholders' equity $79.7M $309M $483M $798M $1.3B $645M $60.2M $159M โˆ’$140M โˆ’$99.3M
Margins
Gross margin โ€” โ€” โ€” โ€” โ€” โ€” โ€” 59.7% 60.8% 64.5%
Operating margin โˆ’173.7% โˆ’153.7% โˆ’102.5% โˆ’38.4% โˆ’88.9% โˆ’110.0% โˆ’121.1% โˆ’100.1% โˆ’60.0% โˆ’44.5%
EBITDA margin โˆ’159.0% โˆ’143.3% โˆ’94.7% โˆ’33.1% โˆ’83.3% โˆ’104.0% โˆ’113.1% โˆ’92.5% โˆ’54.3% โˆ’40.5%
Net margin โˆ’182.7% โˆ’167.0% โˆ’93.8% โˆ’35.3% โˆ’85.9% โˆ’103.0% โˆ’145.6% โˆ’85.0% โˆ’59.0% โˆ’42.4%
FCF margin โˆ’152.4% โˆ’158.3% โˆ’101.9% โˆ’30.7% โˆ’48.9% โˆ’76.0% โˆ’86.1% โˆ’61.3% โˆ’37.2% โˆ’23.7%
Returns
Return on capital โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โˆ’215.1% โˆ’170.1%
Return on capital employed โ€” โˆ’23.7% โˆ’17.2% โˆ’9.3% โˆ’11.6% โˆ’20.4% โˆ’38.4% โˆ’35.7% โˆ’35.2% โˆ’25.6%
Return on equity โˆ’57.9% โˆ’42.9% โˆ’21.5% โˆ’11.8% โˆ’23.5% โˆ’39.6% โˆ’185.7% โˆ’438.1% โˆ’4,584.5% โ€”
Return on assets โ€” โˆ’24.3% โˆ’18.3% โˆ’9.8% โˆ’15.2% โˆ’17.2% โˆ’34.3% โˆ’28.2% โˆ’26.7% โˆ’23.8%
Return on tangible equity โˆ’57.9% โˆ’28.8% โˆ’17.6% โˆ’9.6% โˆ’19.8% โˆ’64.6% โˆ’1,449.4% โˆ’327.5% โ€” โ€”
Growth
Revenue growth โ€” 97.4% 81.9% 136.5% 33.8% 30.3% 20.3% 25.5% 31.0% 32.9%
Share count change โ€” โˆ’3.6% 141.6% 198.0% 7.6% 3.9% 0.9% 9.6% 9.6% 2.1%
Financial health
Interest coverage โˆ’14.5x โˆ’28.4x โˆ’74.3x โˆ’69.7x โˆ’53.5x โˆ’159.5x โˆ’211.2x โˆ’219.1x โˆ’171.9x โˆ’112.2x
Current ratio โ€” 12.4x 10.0x 8.2x 28.3x 5.7x 6.2x 6.5x 4.7x 4.8x
Quick ratio โ€” 12.0x 9.8x 8.0x 27.9x 5.6x 5.9x 6.2x 4.4x 4.6x
Capital allocation
Capex / revenue 7.0% 13.4% 22.3% 8.7% 12.6% 20.1% 17.2% 3.6% 4.7% 4.9%
Stock comp / revenue 7.8% 7.4% 7.6% 7.9% 50.3% 40.5% 21.1% 16.1% 19.0% 16.9%
Quality scores
Piotroski F-score โ€” โ€” 3.0 3.0 2.0 2.0 3.0 4.0 3.0 5.0
Altman Z'' โ€” 10.3 10.2 9.1 5.1 0.4 โˆ’1.5 โˆ’1.7 โˆ’4.1 โˆ’2.6
Accruals ratio โ€” โˆ’3.2% โˆ’2.8% โˆ’3.7% โˆ’8.8% โˆ’7.9% โˆ’18.1% โˆ’9.1% โˆ’12.0% โˆ’13.2%

Source: SEC EDGAR XBRL filings (CIK 0001576280). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open